The Walter and Eliza Hall Institute of Medical Research, Australia
Geoff Lindeman, a clinician-scientist, is Joint Head of the Stem Cells and Cancer Division at the Walter and Eliza Hall Institute. He is also a medical oncologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre. He also has an honorary appointment as Professorial Fellow in the Department of Medicine, University of Melbourne.
His laboratory is studying molecular regulators of normal mammary gland development and cancer, with a particular interest in understanding how mammary stem cells and their progeny contribute to the mammary epithelial cell hierarchy. Using this approach, it should be possible to decipher the molecular and cellular events that lead to breast cancer. Recent work has led to the discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers.
His laboratory is also using patient derived xenograft (PDX) models to test promising anti-cancer agents. Pre-clinical studies using BH3 mimetics has led to an early phase study of he BCL-2 inhibitor venetoclax in breast cancer, currently underway.
Lindeman has been elected as Fellow of the Australian Academy of Health and Medical Sciences and the Australian Academy of Science.